Growth factor receptors as targets for lung cancer therapy

Dao Nguyen, David S. Schrump

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Dysregulated signal transduction of growth factor receptors contributes to the process of malignant transformation by promoting cell proliferation, motility, and invasion through extracellular matrix as well as angiogenesis. Epidermal growth factor receptors (EGFR), and to a lesser extent HER2/neu, is overexpressed in the majority of nonsmall cell lung cancer (NSCLC) compared with normal tissue, making them ideal targets for the development of novel therapeutics for this disease. Multiple clinical trials have demonstrated that antireceptor strategies employing antagonistic monoclonal antibodies or low molecular weight tyrosine kinase inhibitors against EGFR are well tolerated and occasionally result in objective clinical responses in patients with advanced NSCLC. This report provides an overview of the molecular basis and the preclinical evidence supporting clinical development of anti-EGFR therapy as well as results of phase I-III clinical trials of these compounds in treating patients with solid tumors including NSCLC.

Original languageEnglish
Pages (from-to)3-12
Number of pages10
JournalSeminars in Thoracic and Cardiovascular Surgery
Volume16
Issue number1
StatePublished - Mar 1 2004
Externally publishedYes

Fingerprint

Growth Factor Receptors
Non-Small Cell Lung Carcinoma
Lung Neoplasms
Phase III Clinical Trials
Clinical Trials, Phase I
Protein-Tyrosine Kinases
Cell Movement
Extracellular Matrix
Signal Transduction
Therapeutics
Molecular Weight
Monoclonal Antibodies
Cell Proliferation
Clinical Trials
ErbB Receptors
Neoplasms

Keywords

  • Growth factors
  • Lung cancer
  • Molecular therapy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Growth factor receptors as targets for lung cancer therapy. / Nguyen, Dao; Schrump, David S.

In: Seminars in Thoracic and Cardiovascular Surgery, Vol. 16, No. 1, 01.03.2004, p. 3-12.

Research output: Contribution to journalArticle

@article{b1758c66892b4eee81ce9f9763dd8988,
title = "Growth factor receptors as targets for lung cancer therapy",
abstract = "Dysregulated signal transduction of growth factor receptors contributes to the process of malignant transformation by promoting cell proliferation, motility, and invasion through extracellular matrix as well as angiogenesis. Epidermal growth factor receptors (EGFR), and to a lesser extent HER2/neu, is overexpressed in the majority of nonsmall cell lung cancer (NSCLC) compared with normal tissue, making them ideal targets for the development of novel therapeutics for this disease. Multiple clinical trials have demonstrated that antireceptor strategies employing antagonistic monoclonal antibodies or low molecular weight tyrosine kinase inhibitors against EGFR are well tolerated and occasionally result in objective clinical responses in patients with advanced NSCLC. This report provides an overview of the molecular basis and the preclinical evidence supporting clinical development of anti-EGFR therapy as well as results of phase I-III clinical trials of these compounds in treating patients with solid tumors including NSCLC.",
keywords = "Growth factors, Lung cancer, Molecular therapy",
author = "Dao Nguyen and Schrump, {David S.}",
year = "2004",
month = "3",
day = "1",
language = "English",
volume = "16",
pages = "3--12",
journal = "Seminars in Thoracic and Cardiovascular Surgery",
issn = "1043-0679",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Growth factor receptors as targets for lung cancer therapy

AU - Nguyen, Dao

AU - Schrump, David S.

PY - 2004/3/1

Y1 - 2004/3/1

N2 - Dysregulated signal transduction of growth factor receptors contributes to the process of malignant transformation by promoting cell proliferation, motility, and invasion through extracellular matrix as well as angiogenesis. Epidermal growth factor receptors (EGFR), and to a lesser extent HER2/neu, is overexpressed in the majority of nonsmall cell lung cancer (NSCLC) compared with normal tissue, making them ideal targets for the development of novel therapeutics for this disease. Multiple clinical trials have demonstrated that antireceptor strategies employing antagonistic monoclonal antibodies or low molecular weight tyrosine kinase inhibitors against EGFR are well tolerated and occasionally result in objective clinical responses in patients with advanced NSCLC. This report provides an overview of the molecular basis and the preclinical evidence supporting clinical development of anti-EGFR therapy as well as results of phase I-III clinical trials of these compounds in treating patients with solid tumors including NSCLC.

AB - Dysregulated signal transduction of growth factor receptors contributes to the process of malignant transformation by promoting cell proliferation, motility, and invasion through extracellular matrix as well as angiogenesis. Epidermal growth factor receptors (EGFR), and to a lesser extent HER2/neu, is overexpressed in the majority of nonsmall cell lung cancer (NSCLC) compared with normal tissue, making them ideal targets for the development of novel therapeutics for this disease. Multiple clinical trials have demonstrated that antireceptor strategies employing antagonistic monoclonal antibodies or low molecular weight tyrosine kinase inhibitors against EGFR are well tolerated and occasionally result in objective clinical responses in patients with advanced NSCLC. This report provides an overview of the molecular basis and the preclinical evidence supporting clinical development of anti-EGFR therapy as well as results of phase I-III clinical trials of these compounds in treating patients with solid tumors including NSCLC.

KW - Growth factors

KW - Lung cancer

KW - Molecular therapy

UR - http://www.scopus.com/inward/record.url?scp=2642519008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2642519008&partnerID=8YFLogxK

M3 - Article

C2 - 15366682

AN - SCOPUS:2642519008

VL - 16

SP - 3

EP - 12

JO - Seminars in Thoracic and Cardiovascular Surgery

JF - Seminars in Thoracic and Cardiovascular Surgery

SN - 1043-0679

IS - 1

ER -